论文部分内容阅读
新诊断T2DM患者48例,随机分为治疗组(地特胰岛素联合二甲双胍、阿卡波糖)和对照组(瑞格列奈联合二甲双胍、阿卡波糖),治疗12周。结果治疗FBG、2h BG、Hb A1c较治疗前明显下降(P<0.01);治疗组FC-P及2h C-P浓度显著高于对照组(P<0.05),低血糖发生次数显著低于对照组(P<0.05)。结论地特胰岛素联合口服降糖药治疗有效降低血糖,逆转受损的β细胞功能,且安全性好。
Forty-eight newly diagnosed T2DM patients were randomly divided into treatment group (detemir plus metformin and acarbose) and control group (repaglinide plus metformin and acarbose) for 12 weeks. Results The FBG, 2h BG and Hb A1c in treatment group were significantly lower than those before treatment (P <0.01). The concentrations of FC-P and 2h CP in treatment group were significantly higher than those in control group (P <0.05), and the incidence of hypoglycemia was significantly lower than that in control group P <0.05). Conclusion The combination of detemir insulin and oral hypoglycemic agents can effectively reduce blood glucose, reverse the function of damaged β-cells and has good safety.